- Clinical Expertise
- Lymphoma (Hodgkin's and non-Hodgkins)
- Leukemia & Myeloma
- Board Certifications
- Internal Medicine
- Medical Oncology
- Appointments
- Associate Professor of Medicine, Columbia University Medical Center
- Education
- B.S., 1982, Manhattan College, Bronx, NY
- M.S., 1984, Fairleigh Dickinson, Rutherford, NJ
- Ph.D., 1990, New York University School of Medicine, New York, NY
- M.D., 1994, University of Medicine & Dentistry, New Brunswick, NJ
- Internship & Residency
- Internal Medicine, 1996, New York Presbyterian Hospital, Weil Cornell Medical Center, New York, NY
Owen A. O'Connor, M.D., Ph.D.
NEW PATIENTS TEL (212) 305-5098
ADMINISTRATIVE OFFICE TEL (212) 305-3653
FAX (212) 851-4710
- OUTPATIENT OFFICE LOCATION
- Herbert Irving Pavilion 9 919
- 161 Fort Washington Ave
- PHYSICIAN SUMMARY
- Owen A. O’Connor, M.D., Ph.D., Associate Professor of Medicine, is the Leader of the Lymphoid Development and Malignancy Program in the Herbert Irving Comprehensive Cancer Center at Columbia University, and Chief of the Lymphoma Service in the College of Physicians and Surgeons at Columbia University and The New York Presbyterian Hospital. His clinical and research interests focus on the discovery and development of novel drugs for the treatment of hematologic malignancies.
Dr. O’Connor received his Ph.D. from the New York University School of Medicine in Biochemical Toxicology and Chemical Carcinogenesis, and his M.D. from the University of Medicine and Dentistry of New Jersey. He then went on to do a medical internship and residency at The New York Hospital-Cornell University Medical Center. Following his medical residency, he did a fellowship in Medical Oncology at the Memorial Sloan Kettering Cancer Center, where he was Chief Fellow from 1997-1998, and a Fellowship in Clinical Pharmacology at the New York Hospital-Cornell University Medical School. During his fellowship, he worked in the laboratory of Dr. Joseph R. Bertino. Prior to joining the faculty at Columbia University, we was an Attending Physician in the Department of Medicine on the Lymphoma Service, and head of the Laboratory of Experimental Therapeutics for the Lymphoproliferative Malignancies at Memorial Sloan Kettering Cancer Center.
Dr. O’Connor maintains a laboratory program focused on the discovery of novel drugs for the treatment of non-Hodgkin's lymphoma and Hodgkin's disease using unique animal models of lymphoma and high-throughput screening approaches. Clinically, he is focused on the conduct of Phase I and II clinical trials, with an emphasis on pharmacokinetic and pharmacodynamic studies. He has a particular interest in the development of proteasome inhibitors, histone deacetylase inhibitors and Bcl-2 targeted drugs for the treatment of lymphoproliferative malignancies. To date, his studies on the novel proteasome inhibitor bortezomib and the novel histone deacetylase inhibitor Vorinostat (SAHA) have led to recent FDA approval of these drugs for the treatment of mantle cell lymphoma and cutaneous T-cell lymphoma.
Dr. O'Connor is an internationally recognized authority in the field. He is a member of several professional societies, including the American Association for Cancer Research (AACR), the American Society for Clinical Oncology (ASCO), the American Society of Clinical Pharmacology and Therapeutics (ASCP&T), and the American Society for Hematology (ASH). He serves on the Lymphoma and Pharmacology and Experimental Therapeutics (PET) Committees for the CALGB. He is a member of the Executive Committee of the Mantle Cell Lymphoma Consortium for the Lymphoma Research Foundation, and serves as a member of their Scientific Advisory Board. He is Senior Editor for Clinical Cancer Research, and is also on the Editorial Board for the Journal of Clinical Oncology and Leukemia and Lymphoma. To date, Dr. O’Connor has published nearly 100 articles in numerous journals, including Proceedings of the National Academy of Science; Journal of Clinical Oncology; British Journal of Hematology, Leukemia and Lymphoma; Clinical Cancer Research; Environmental Science and Technology and Environmental Toxicology and Chemistry. His research has resulted in numerous abstracts of papers presented at National and International meetings, and numerous invitations to lecture about his work around the world. Dr. O’Connor is the recipient of several honors and awards, including the prestigious Scholar in Clinical Research Award from the Leukemia and Lymphoma Society, a Merit Award from the American Society for Clinical Oncology, and the William Guy Forbeck Scholar Award, and co-recipient of the Ellen Glesby Cohen Leadership Award from the Lymphoma Research Foundation for his contributions to mantle cell lymphoma.